500 related articles for article (PubMed ID: 33400241)
1. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
Hanzel J; Ma C; Casteele NV; Khanna R; Jairath V; Feagan BG
Drugs; 2021 Feb; 81(3):333-347. PubMed ID: 33400241
[TBL] [Abstract][Full Text] [Related]
2. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
3. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
[TBL] [Abstract][Full Text] [Related]
4. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
5. Skin Manifestations of Inflammatory Bowel Disease.
Greuter T; Navarini A; Vavricka SR
Clin Rev Allergy Immunol; 2017 Dec; 53(3):413-427. PubMed ID: 28643285
[TBL] [Abstract][Full Text] [Related]
6. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.
Rogler G; Singh A; Kavanaugh A; Rubin DT
Gastroenterology; 2021 Oct; 161(4):1118-1132. PubMed ID: 34358489
[TBL] [Abstract][Full Text] [Related]
7. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
Barrie A; Regueiro M
Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
He R; Zhao S; Cui M; Chen Y; Ma J; Li J; Wang X
Front Immunol; 2023; 14():1234535. PubMed ID: 37954590
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab-Induced De Novo Extraintestinal Manifestations.
Diaz LI; Keihanian T; Schwartz I; Bin Kim S; Calmet F; Alejandra Quintero M; Abreu MT
Gastroenterol Hepatol (N Y); 2020 Feb; 16(2):75-81. PubMed ID: 34035705
[No Abstract] [Full Text] [Related]
10. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.
Siemanowski B; Regueiro M
Curr Treat Options Gastroenterol; 2007 Jun; 10(3):178-84. PubMed ID: 17547856
[TBL] [Abstract][Full Text] [Related]
11. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.
Trikudanathan G; Venkatesh PG; Navaneethan U
Drugs; 2012 Dec; 72(18):2333-49. PubMed ID: 23181971
[TBL] [Abstract][Full Text] [Related]
13. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.
Greuter T; Vavricka SR
Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):307-317. PubMed ID: 30791773
[TBL] [Abstract][Full Text] [Related]
14. Biologics for extraintestinal manifestations of IBD.
Vavricka SR; Scharl M; Gubler M; Rogler G
Curr Drug Targets; 2014; 15(11):1064-73. PubMed ID: 25198785
[TBL] [Abstract][Full Text] [Related]
15. The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Zheng DY; Wang YN; Huang YH; Jiang M; Ma YN; Dai C
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38740543
[TBL] [Abstract][Full Text] [Related]
16. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease.
Andrisani G; Guidi L; Papa A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):890-901. PubMed ID: 22953637
[TBL] [Abstract][Full Text] [Related]
18. Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It.
Migliorisi G; Vella G; Dal Buono A; Gabbiadini R; Busacca A; Loy L; Bezzio C; Vinciguerra P; Armuzzi A
Cells; 2024 Jan; 13(2):. PubMed ID: 38247834
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
Chateau T; Bonovas S; Le Berre C; Mathieu N; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2019 Dec; 13(12):1569-1577. PubMed ID: 31076751
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
